Research Article
Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients
Table 1
Detailed clinicopathological features of Enza-treated CRPC patients with different CXCR7 expression profile.
| | Biomarker | CXCR7+ () | CXCR7- () | Statistical analysis | | Median (range) | Median (range) | | value |
| | Age at diagnosis (years) | 74 (67~84) | 75 (66~81) | 0.275 | 0.9112 | | Follow-up (months) | 24 (12~42) | 28.5 (12~42) | 0.637 | 0.3926 | | Count (%) | Count (%) | | value | | Previous treatment | | Brachytherapy | 21 (44.7) | 12 (37.5) | 3.398 | 0.1829 | | Radical radiotherapy | 9 (19.1) | 12 (37.5) | | Endocrine therapy | 17 (36.2) | 8 (25.0) | | Serum PSA (ng/mL) | | ≤20 | 8 (17.0) | 6 (18.8) | 0.296 | 0.8624 | | 20~50 | 17 (36.2) | 13 (40.6) | | ≥50 | 22 (46.8) | 13 (40.6) | | Gleason score | | ≤6 | 1 (2.1) | 0 (0) | 2.463 | 0.2919 | | =7 | 2 (4.3) | 4 (12.5) | | ≥8 | 44 (93.6) | 28 (87.5) | | Lymph node metastasis | | Yes | 13 (27.7) | 11 (34.4) | 0.406 | 0.5240 | | No | 34 (72.3) | 21 (65.6) | | Distant metastasis | | Yes | 7 (14.9) | 9 (28.1) | 2.064 | 0.1508 | | No | 40 (85.1) | 23 (71.9) |
|
|
Note: all cases were strictly accordance with the inclusion and exclusion criteria.
|
